QGEN changes
Pick any two versions below to diff them.
- Price
- $46.13 → $50.34(+9.1%)
- Recent events
- added: Oct 21, 2026: EQT Private Equity offered EUR 46.50 per share in cash for Qiagen, a premium of 40.3%. The offer values Qiagen at about EUR 10.8 billion including debt. Both boards recommend the offer. The companies expect the deal to close in mid-2027. Sep 24, 2026: QIAGEN launched QIAmini, a system that automates sample preparation for small batches. Four days later, it received U.S. FDA clearance for a new QIAstat-Dx bacteria panel, which completes its U.S. portfolio of bloodstream infection panels. Sep 18, 2026: QIAGEN called an Extraordinary General Meeting on November 6, 2026, to appoint Jonathan M. Pratt to the Managing Board. Aug 24, 2026: QIAGEN appointed Jonathan M. Pratt as CEO from September 1, 2026. He was CEO of Filtration Group and earlier led the Waters Division of Waters Corporation and Beckman Coulter Life Sciences. Thierry Bernard stepped down as CEO and supports the transition until the end of 2026. QIAGEN reaffirmed its Q3 and full-year 2026 outlook and said that the strategic review of the Supervisory Board continues. Aug 5, 2026: QIAGEN reported Q2 2026 results. Net sales were $535 million, unchanged from Q2 2025, above the outlook for a decline of about 2% at constant exchange rates. The growth pillars grew about 5%. Adjusted EPS was $0.62 and the adjusted operating margin was 29.4%. QIAGEN reaffirmed its 2026 outlook. Apr 27, 2026: QIAGEN reported preliminary Q1 2026 results and cut its 2026 outlook. Net sales were $492 million, down 1% at constant exchange rates, and QuantiFERON sales fell 5% because of lower immigration testing demand. The new outlook is net sales growth of about 1% to 2% at constant exchange rates and adjusted EPS of at least $2.43.